BridgeBio Pharma and National Resilience agreed to collaborate on the manufacture and advancement of BBP-812, an investigational adeno-associated virus (AAV) 9 gene therapy for Canavan disease, and BBP-631, an investigational AAV 5 gene therapy for congenital adrenal hyperplasia (CAH).
BridgeBio will transfer its manufacturing process for its lead AAV-based gene therapy candidates to Resilience’s network of gene therapy sites. As part of a cost and risk-sharing framework, Resilience will provide in-kind manufacturing services and receive future development and approval milestones and low-to-mid single-digit royalties on BBP-631 and BBP-812. Resilience will support the ongoing clinical development manufacturing needs and will serve as the primary commercial manufacturer for both programs if successful.
“Our partnership with BridgeBio seeks to accelerate development of innovative therapeutic options for patients in need,” said Rahul Singhvi, ScD, CEO of Resilience. “We are pleased to partner with a gene therapy and rare disease leader, and we are inspired by their passion to deliver medicines to patients.”
Beyond BBP-812 and BBP-631, Resilience will also be the primary manufacturer for future clinical projects across BridgeBio’s gene therapy portfolio.
“Manufacturing is the most critical and costly aspect of developing gene therapy for patients with a serious unmet need,” noted Eric David, MD, CEO of BridgeBio Gene Therapy. “We conduct process development, analytical development, and optimization in our own labs, and with this partnership, we can now hand these programs off to one of the most trusted partners in the industry for scale up and commercial manufacturing. This allows us to accelerate the development of our gene therapy portfolio in a capital-efficient and sustainable way with the hope of providing medicines more quickly.”